Mutual funds betting big on recently listed and new-age companies

Mutual funds betting big on recently listed and new-age companies



Fund managers placed big bets on new-age companies and recently listed firms in August with three such stocks featuring in the top five most bought stock list of mutual funds (MFs) last month.


Ola Electric, which listed on August 9, was the second most bought stock as fund managers lapped up over Rs 2,740 crore worth of shares. Newly listed FirstCry saw MFs buying 40 million shares worth Rs 2,550 crore. Zomato ranked fourth in the list as MFs deployed Rs 2,500 crore in the stock.

 


Axis Bank led the top buy list as MFs bought Rs 3,120 worth of stocks. However, its larger peer HDFC Bank saw MFs pulling out as much as Rs 8,370 crore. The stock, which has struggled to perform in recent years, saw several fund houses cutting allocation after making significant buying for six successive months. Quant MF completely exited the stock in August months after betting big.  Other stocks in the most sold list included Bharti Airtel, Zydus Lifesciences, Indus Towers, Coal India and Dixon Technologies.

 


Fund houses completely exited Adani Enterprises while making significant buying in Adani Energy Solutions.

In August, MFs bought domestic equities worth over Rs 35,600 crore and alongside foreign institutional investors (FIIs) sold Rs 2,700 in the Indian secondary market, the report noted.

First Published: Sep 13 2024 | 11:13 PM IST



Source link

Sebi launches centralized fee collection for investment advisers, analysts

Sebi launches centralized fee collection for investment advisers, analysts


Sebi: Representative Image | (Photo: Shutterstock)


Market regulator Sebi on Friday announced rolling out a new system — Centralized Fee Collection Mechanism — to facilitate collection of fees by Investment Advisers (IAs) and Research Analysts (RAs) from their clients on an optional basis.


Under this mechanism, clients will pay fees to IAs/RAs, through a designated platform or portal administered by a recognised Administration and Supervisory Body (ASB), the regulator said in a circular.


The move came in response to the growing interest in the securities market and the need for greater transparency in fee payments.


The markets regulator said that BSE would specify the operational framework for the mechanism on or before September 23 and make the mechanism operational from October 1.

 


The mechanism has been co-created by BSE Ltd with the help of various stakeholders.


While using this mechanism is optional, Sebi asked ASB to take steps to encourage clients and the registered IAs and RAs to avail the services of this mechanism.


Further, registered IAs and RAs will encourage their clients to use this mechanism, it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Sep 13 2024 | 10:53 PM IST



Source link

Northern Arc Capital gets Rs 229 cr from anchor investors ahead of IPO

Northern Arc Capital gets Rs 229 cr from anchor investors ahead of IPO



Non-bank financial institution Northern Arc Capital on Friday said it has collected Rs 229 crore from anchor investors, days before the opening of its share-sale for public subscription.

 


SBI General Insurance Company, SBI Life Insurance Company, Reliance General Insurance Company, Kotak Mahindra Life Insurance Company, Goldman Sachs (Singapore) Pte, Societe Generale, and Quant Mutual Fund are among the anchor investors.

 


According to a circular uploaded on BSE’s website, the company has allotted 8.702 mn equity shares to 15 funds at Rs 263 apiece, which is also the upper end of the price band. This aggregates the transaction size to Rs 229 crore.

 

 


The Rs 777-crore IPO of the Chennai-based company will open for public subscription on September 16 and conclude on September 19. The price has been fixed in the range of Rs 249 to Rs 263 per share.

 


The IPO is a combination of a fresh issue of equity shares valued at Rs 500 crore and an Offer For Sale (OFS) of up to 10,532,320 equity shares worth Rs 277 crore, at the upper end of the price band, by investor shareholders. This aggregates the issue size to Rs 777 crore.

 


Those offering shares through the OFS are Leapfrog Financial Inclusion India (II) Ltd, Accion Africa-Asia Investment Company, Eight Roads Investments Mauritius II Ltd, Sumitomo Mitsui Banking Corporation, 360 ONE Special Opportunities Fund (formerly known as IIFL Special Opportunities Fund), and Dvara Trust.

 


Proceeds from the fresh issue would be used to meet future capital requirements of the company towards onward lending.


“The price band for the offer is at Rs 249 to Rs 263 per equity share,” Northern Arc Capital said in a statement.

 


Investors have the option to bid for a lot size of 57 equity shares and in multiples thereafter.

 


Registered with the RBI as a systemically important, the company is a non-deposit taking non-banking finance company (NBFC) and has been operating in the financial inclusion space for over a decade.

 


Northern Arc is a leading player amongst the country’s diversified NBFCs, with a business model diversified across offerings, sectors, products, geographies and borrower segments. It provides access to credit to under-served households and businesses directly and indirectly through Originator Partners.

 


Northern Arc Capital filed draft papers with Sebi in July 2021 to float its maiden public issue. It got the regulator’s nod to float the public issue in September same year. However, it didn’t go ahead with the launch.

 

ICICI Securities, Axis Capital and Citigroup Global Markets India are the book-running lead managers to the issue.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Sep 13 2024 | 10:27 PM IST



Source link

Missed Market Turning Points in our Mid-cap Fund: DSP MF’s Kalpen Parekh

Missed Market Turning Points in our Mid-cap Fund: DSP MF’s Kalpen Parekh


bl.portfolio caught up with Kalpen Parekh, MD and CEO, DSP Mutual Fund, recently.  In this conversation, he elaborates on his investment philosophy as well as the fund house’s. He believes mean reversion to be the iron law of markets and a counter cyclical approach to investing, followed by the fund house, would help use this principle in their favour, he reasons. Excerpts:

Profile

Kalpen Parekh has over 19 years of experience in sales across client segments, distribution and marketing. He was previously MD and Head of Sales & Marketing at IDFC Mutual Fund. He has also served in Birla Sun Life AMC and ICICI Pru AMC after beginning his career with L&T Finance. He holds a Master’s Degree in Management Studies in Finance from the Narsee Monjee Institute of Management Studies, as well as a Bachelor’s Degree in Chemical Engineering from Bharati Vidyapeeth, Pune.

What is your investment philosophy?

I want to be a permanent investor — an investor every month, every year for a decadal/ multi-decadal time horizon. Every day, week or month, something or the other will happen as markets are integrated with the rest of the world. I don’t want to respond to all that because I have so far never been able to predict what will happen nor will I be able to do it in future. However, two things are generally predictable with a reasonable amount of certainty. One, if you buy an asset class at higher bands of valuation in its cycle, generally future returns are lower and vice-versa; two, if you buy good-quality asset class or good-quality businesses, your chances of survival are higher.

With this very simplistic philosophy, I try to do my investing. When equities are expensive, I will be more into hybrid funds. If markets are cheap, even if there is bad news floating around, I will probably prefer to be more aggressive in my equity portfolio.

What are the metrics you look at, to judge whether markets are cheap or expensive?

In history, we have seen the valuation boundaries for the Nifty from 12 times in a bear market to 25-27 times in a bull market peak, with the middle somewhere at 17-18 times. In the last 10 years, the average has been closer to 20 times, among the key reasons being that India has relatively better macro variables and prospects than rest of the world. So, a lot of money is chasing a few good stocks and instead of 17-18 being the average, it has moved up to 21-22 in the last decade or more.

But when you buy something at an aggregate of 25 times, the earnings yield is lower than what it is at, say, 15 times. So, the room for valuation re-rating is relatively lower. And if the room for valuation re-rating is lower, then I have to rely on only one pillar for returns, which is profit growth. If I look at the 25-year history of our markets, generally we are a country with 15 per cent return on equity and around 12-13 per cent profit growth. So, if you were a single company earning 15-16 per cent and are really growing at 12-13 per cent over long periods of time, then 17-18 times is the multiple one would have given. Vis-à-vis that, we are higher now. So, at such points in time, it’s better to be slightly prudent. Overall, in my portfolio, I would have 65-70 per cent in equities. And the balance would be in bonds and gold.

Of course, there will be exceptions where companies at high valuations still make money, but mean reversion is a very big iron law of markets.

As a fund house, do you believe in contrarian investing? Your launches in recent years are all focused on beaten-down themes and your mid-cap fund has been an underperformer at a time when the segment has done very well…

We do not want to have any labels. We try to do what makes sense to us at any point in time. Many times, we realise that our brain wants to invest in past returns because that gives us comfort. But those returns have already happened. So, you can say that we are a slightly cautious/ conservative fund house and launch counter-cyclical funds because mean reversion, like I said, is a very fundamental force. The idea is to exploit mean reversion in our favour rather than becoming victims of it.

On the mid-cap fund, particularly in the last three-four years post Covid, we are not happy with our outcomes. I completely admit that we have underperformed relevant peers. Having said that, in the last four months we have caught up very sharply. But that’s too short a period to really say much about.

We missed some turning points in the market. There has been a bias against investing in PSUs because we have seen long stretches of poor capital allocation. They were cheap for a long period of time and when they started moving up, we were a bit late in catching up on that. Besides, some themes, like engineering and industrials, we were very early to get in and also early to get out. So these are two areas where maybe we could have been better in our execution. 

Besides, generally, we are very long-term investors. If we like the broad history of the company and the management, even if they’re going through a rough patch in their business, we believe that they have the acumen to take the right decisions and turn it around (and hold on).

This time around, that has not completely worked. There is a decisive slowdown in many sectors which is taking longer to turn around than what it has been in the past. We have improved our tools and techniques to be a bit more agile and which is reflected in our returns in the last few months.

®

In recent quarters, support to bottom-line growth from lower commodity prices has weaned off. Going forward, do you expect demand to pick up and support the bottom-line or are you expecting a slowdown in earnings?

Incrementally, we are seeing a slowdown in both revenue and profit growth, and hence we feel that for at least in the foreseeable future, overall profit growth will come down closer to 10-12 per cent and not stay at the 18 per cent levels we have seen in the past. Very long-term profit growth rates for the country are around 12-14 per cent, as discussed earlier. We are now moderating on revenue as well as profit growth and that’s why we have been a bit conservative in our approach on either product launches or on guiding investors to invest for the longer term and not expect similar rates of return that we have seen in the last few years.

On private capex, as much as the government seems to be pushing and the balance sheets also seem ready, what is preventing the private sector from going all out?

While the private sector is in the best of its shape from a balance sheet point of view to do large-scale capex, lack of visibility on consumption trends or a strong consumption cycle may be preventing them. Secondly, I think a lot of companies have become more disciplined or more respectful of capital allocations. They are looking to maintain higher cash flows, operate at lower leverage and focus on higher ROIs (return on investments) and which is what markets are supporting through higher valuations. Also, post Covid, we have seen leverage across households rise on the one hand and employment growth also has not been very strong. A large part of that employment reversal post-Covid, has happened in agriculture, which is giving a weak input to consumption trends. So, we should not extrapolate just that because government capex has happened, private capex also will happen at high growth rates.





Source link

Zydus enters into exclusive licensing and supply agreement with Viwit

Zydus enters into exclusive licensing and supply agreement with Viwit


For generic versions of GADAVIST™ and DOTAREM?

Zydus Lifesciences announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals (Viwit), an innovation driven biopharmaceutical and healthcare company, for gadobutrol injection (generic version of GADAVIST™) and gadoterate meglumine injection (generic version of DOTAREM) for the US market.

As per the terms of the agreement, Viwit will be responsible for ANDA submission, manufacturing and supplying the generic versions of GADAVIST™ and DOTAREM, following the receipt of requisite regulatory approval. Zydus will exclusively market, distribute, and sell these products in the US market. Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market.

 

The total addressable market opportunity for gadobutrol injection is estimated at US$ 120 million, and for gadoterate meglumine injection at US$ 117 million in the US market (as per IQVIA MAT Jul – 2024).

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Sep 13 2024 | 9:09 PM IST



Source link

YouTube
Instagram
WhatsApp